Searches both Title and Fulltext content
Takes you to the requested Key Event
Clear Search Terms Clears search terms and filters

Showing 1 to 25 of 1921 Key Events

Clear Table Filters
ID Title Event Component Count Biological Organization Created At Last Updated AOPs
2408 Increase, Adipose lipolysis
0 Tissue Feb 10, 2026 Feb 10, 2026
2419 Decreased, Retinoic Acid Receptor Activation
0 Tissue Apr 22, 2026 Apr 23, 2026 398: Decreased ALDH1A (RALDH) activity leading to decreased fertility via disrupted meiotic initiation of fetal oogonia
2416 human amyotrophic lateral sclerosis (ALS)
0 Individual Mar 30, 2026 Mar 30, 2026 636: Increase in reactive oxygen species (ROS) leading to human amyotrophic lateral sclerosis (ALS)
2414 COL3A1 Signaling Pathway
0 Molecular Mar 25, 2026 Mar 25, 2026 638: Co-exposure to microplastics and cadmium leading to progression from NAFLD to liver tumorigenesis
2423 Hepatic SHP, decreased
0 Cellular Apr 22, 2026 Apr 22, 2026 232: NFE2/Nrf2 repression to steatosis
2424 Hepatic CYP7A1, increased
0 Cellular Apr 22, 2026 Apr 22, 2026 642: Intestinal FXR inhibition leading to steatohepatitis via gut‑liver axis dysregulation
2425 Intrahepatic bile acid burden, increased
0 Cellular Apr 23, 2026 Apr 23, 2026 642: Intestinal FXR inhibition leading to steatohepatitis via gut‑liver axis dysregulation
2426 Hepatic BSEP (ABCB11), decreased
0 Cellular Apr 23, 2026 Apr 23, 2026 642: Intestinal FXR inhibition leading to steatohepatitis via gut‑liver axis dysregulation
2427 Bile acid composition in bile and intestine, altered
0 Cellular Apr 23, 2026 Apr 23, 2026 642: Intestinal FXR inhibition leading to steatohepatitis via gut‑liver axis dysregulation
2428 Gut derived PAMPs, increased
0 Cellular Apr 23, 2026 Apr 23, 2026 642: Intestinal FXR inhibition leading to steatohepatitis via gut‑liver axis dysregulation
2422 Ileal FGF15/FGF19 secretion, decreased
0 Cellular Apr 22, 2026 Apr 22, 2026 642: Intestinal FXR inhibition leading to steatohepatitis via gut‑liver axis dysregulation
2410 Increase, 11β-Hydroxysteroid dehydrogenase type 1 activity
0 Molecular Feb 18, 2026 Feb 18, 2026
2409 Decrease, 11β-Hydroxysteroid dehydrogenase type 2 activity
0 Molecular Feb 10, 2026 Feb 26, 2026 630: Decreased 11β-Hydroxysteroid dehydrogenase type 2 activity leading to MASLD progression via insulin resistance-associated mitochondrial dysfunction
2411 Increase, Circulating active glucocorticoid availability
0 Organ Feb 18, 2026 Feb 24, 2026 None
2407 Increase, Cirrhosis
0 Organ Feb 10, 2026 Feb 11, 2026
2406 Increase, Regenerative nodule formation
0 Tissue Feb 10, 2026 Feb 10, 2026
2405 Increase, Hepatocellular lipotoxicity
0 Cellular Feb 10, 2026 Feb 10, 2026
2404 Increase, kidney fibrosis
0 Tissue Feb 6, 2026 Feb 27, 2026 622: Calcineurin inhibitor induced nephrotoxicity leading to kidney failure
2403 Metabolic impairment
0 Cellular Feb 6, 2026 Feb 6, 2026 622: Calcineurin inhibitor induced nephrotoxicity leading to kidney failure
2398 Reduced antibody production
0 Cellular Dec 3, 2025 Dec 3, 2025 618: PPARgamma activation leads to a diminished vaccine response
2397 Diminished vaccine response
0 Individual Dec 3, 2025 Dec 3, 2025 618: PPARgamma activation leads to a diminished vaccine response
2362 Redox cycling of a chemical by mitochondria
0 Molecular Sep 5, 2025 Oct 3, 2025 593: Redox cycling of a chemical by mitochondria leads to degeneration of nigrostriatal dopaminergic neurons
2395 Diminished proliferation of activated B lymphocytes
0 Cellular Dec 3, 2025 Dec 3, 2025 618: PPARgamma activation leads to a diminished vaccine response
2394 Diminished survival of naive B lymphocytes
0 Cellular Dec 3, 2025 Dec 3, 2025 618: PPARgamma activation leads to a diminished vaccine response
2392 Depression
0 Individual Nov 9, 2025 Nov 10, 2025 None